BLADDER

Alliance-A031501: A Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation

The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of a muscle invasive bladder cancer. MK-3475 is a drug that uses a person’s own immune system to treat cancer.

Learn more about Alliance-A031501 trial or call the Protocol Office at 484-628-8193.

PROSTATE

ECOG/ACRIN-EA8153: Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: the CHAARTED2 TrialCancer Previously Treated with Docetaxel

The purpose of this research study is to compare any good or bad effects of using the chemotherapy drug cabazitaxel (also known as Jevtana®) with the usual approach of the hormone-based therapy abiraterone acetate (also known as Zytiga®) in combination with prednisone on patients with advanced prostate cancer that have already undergone treatment with hormone therapy and the chemotherapy drug docetaxel.

Learn more about the ECOG/ACRIN-EA8153 trial or call the Protocol Office at 484-628-8193.

 

NRG-GU002: Phase II-III trial of adjuvant radiotherapy and androgen deprivation following radical prostatectomy with or without adjuvant docetaxel

The purpose of this study is to compare any good and bad effects of using docetaxel along with radiation therapy and hormone suppression therapy to using radiation and hormone suppression therapy alone in men with a high chance of prostate cancer recurrence after surgically removing the prostate.

Learn more about the NRG-GU002 trial or call the Protocol Office at 484-628-8193.

NRG-GU005: Phase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer.

The purpose of this study is to compare any good and bad effects of using stereotactic body radiation therapy (SBRT), a technique that gives treatment in a shorter amount of time compared to the usual radiation therapy.

Learn more about the NRG-GU005 trial or call the Protocol Office at 484-628-8193.

NRG-GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy.

The purpose of this study is to compare the use of hormone therapy and radiation therapy (usual treatment) to the use of apalutamide and abiraterone acetate with prednisone plus the usual treatment.

Learn more about the NRG-GU008 trial or call the Protocol Office at 484-628-8193.

TJU-17C.072: Prostate cancer outcomes: An international registry to improve outcomes in men with advanced prostate cancer (IRONMAN)

The purpose of this study is to learn more about prostate cancer and to describe the use of different therapies for advanced prostate cancer internationally.

Learn more about the TJU-17C.072 trial or call the Protocol Office at 484-628-8193.

RENAL

ECOG/ACRIN-EA8143: A phase 3 randomized study comparing perioperative nivolumab vs observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC)

The purpose of this study is to compile the good and bad results of adding the drug nivolumab before and after surgery to remove the kidney. Those results will then be compared to the usual approach of surgically removing the kidney, followed by standard postoperative follow-up and monitoring. Nivolumab may stimulate the immune system to attack any cancer cells remaining after surgery.

Learn more the ECOG/ACRIN-EA8143 trial or call the Protocol Office at 484-628-8193